Whole Brain Radiation

RADIATION4 trials

Conditions

Brain MetastasesBreast CancerGlioblastoma MultiformeMalignant Glioma

Phase 1

Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer

CompletedNCT00470847

Nancy Lin, MDBrain Metastases, Breast Cancer

Start: 2007-04-30End: 2012-06-30Updated: 2014-05-22

Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme

CompletedNCT01800695

AbbVieGlioblastoma Multiforme

Start: 2013-04-02End: 2017-06-19Updated: 2017-11-21

Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma

CompletedNCT02590263

AbbVieGlioblastoma Multiforme, Malignant Glioma

Start: 2015-08-24End: 2020-08-27Updated: 2020-09-03

Unknown Phase

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

Active, not recruitingNCT03075072

Dana-Farber Cancer InstituteBrain Metastases

Start: 2017-04-10End: 2025-09-30Target: 196Updated: 2024-10-23

2026-02-19

NCOG-20. Stereotactic radiation versus hippocampal avoidant whole brain radiation in patients with 5-20 brain metastases: Cognitive outcomes of 12-month survivors

Neuro-Oncology2025-11-01

Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial.

Journal of Clinical Oncology2025-05-2813 citations

Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial

Cancer Science2021-10-0722 citations

Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol.

2020-10-3014 citations

Feasibility of hippocampal avoidance whole brain radiation in patients with hippocampal involvement: Data from a prospective study.

2020-08-074 citations

Phase I/II study of depatuxizumab mafodotin (ABT-414) monotherapy or combination with temozolomide in Japanese patients with/without <i>EGFR</i>-amplified recurrent glioblastoma.

Journal of Clinical Oncology2019-05-205 citations

ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414

Neuro-Oncology2018-11-012 citations

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with<i>EGFR</i>-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

Neuro-Oncology2018-06-1194 citations

ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (ABT-414) IN GLIOBLASTOMA (GBM)

Neuro-Oncology2017-11-018 citations

PDCT-02. EVALUATION OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN CHILDREN WITH HIGH GRADE GLIOMA (HGG) AND DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Neuro-Oncology2017-11-011 citations

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

2017-10-2699 citations

Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.

Journal of Clinical Oncology2017-05-209 citations

OS07.4 Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified (EGFRamp), recurrent glioblastoma (rGBM)

Neuro-Oncology2017-04-015 citations

P09.25 Identifying the correct patient (pt) population for ABT414: biomarker assays for epidermal growth factor receptor (EGFR) in pts with glioblastoma (GBM)

Neuro-Oncology2017-04-012 citations

ACTR-07. EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRamp), RECURRENT GLIOBLASTOMA (rGBM)

Neuro-Oncology2016-11-012 citations

Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).

Journal of Clinical Oncology2016-05-209 citations

ATNT-01ABT-414 MONO- OR COMBINATION THERAPY WITH TEMOZOLOMIDE (TMZ) RECHALLENGE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM) AND AMPLIFIED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR): A PHASE I STUDY

Neuro-Oncology2015-11-014 citations

Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).

Journal of Clinical Oncology2015-05-2020 citations

A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).

Journal of Clinical Oncology2014-05-2022 citations

Whole Brain Radiation

Sponsors

Conditions

Phase 1

Unknown Phase

Related Papers